SIRT1 Modulators for CD4+ T-Cell Immune Response Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
HIV-1 infection leads to continuous viral replication and CD4+ T-cell depletion due to immune activation, with elevated levels of activation markers correlating with accelerated disease progression and shortened survival, and existing methods fail to effectively modulate CD4+ T-cell activation and differentiation.
Innovation Solution
Administering SIRT1 inhibitors or activators to modulate the immune response by targeting SIRT1's deacetylase activity, which affects CD4+ T-cell activation and differentiation, thereby influencing HIV transcription and immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If SIRT1 inhibitors are administered to increase immune response, then immune response is enhanced, but risk of immune hyperactivity increases
Solution Approach 1:
The patent employs dynamic modulation of SIRT1 activity rather than static inhibition, allowing the immune system to respond flexibly to different pathological conditions. The method adjusts immune response intensity based on the specific disease state, enabling effective anti-HIV immunity while preventing harmful immune hyperactivity in autoimmune conditions.
Solution Approach 2:
The patent changes the physiological parameters of immune cell function by modulating SIRT1 deacetylase activity. By altering acetylation levels of key transcription factors like NF-κB and FoxP3, the method transforms immune cell behavior from a fixed state to a controllable variable state, achieving therapeutic immune modulation without causing harmful hyperactivity.
2Object-affected harmful factors
If SIRT1 activators are administered to reduce immune response, then immune hyperactivity is controlled, but immune response effectiveness may be reduced
Solution Approach 1:
The patent uses dynamic activation of SIRT1 to control immune hyperactivity only when needed, rather than continuous suppression. This allows the immune system to maintain effectiveness for pathogen clearance while being activated, and only receives SIRT1 activation treatment when immune hyperactivity becomes harmful, preserving immune response effectiveness.
Solution Approach 2:
The patent extracts the harmful aspect of immune response (hyperactivity) from the beneficial aspect (effective immune defense) by selectively activating SIRT1 only in pathological conditions of immune hyperactivity. This separation allows control of harmful effects while preserving immune effectiveness for actual threats.
3Reliability
If existing methods are used to modulate CD4+ T-cell activation, then some immune modulation is achieved, but effectiveness in controlling HIV replication and preventing CD4+ T-cell depletion is insufficient
Solution Approach 1:
The patent changes the molecular parameters of CD4+ T-cell activation by targeting SIRT1 deacetylase activity and acetylation status of transcription factors. This fundamental parameter change at the epigenetic level creates more effective immune modulation compared to existing methods, leading to better control of HIV replication and prevention of CD4+ T-cell depletion.
Solution Approach 2:
The patent introduces SIRT1 deacetylase activity as an intermediary mechanism to control CD4+ T-cell activation. By using this enzymatic activity as a mediator between immune signals and transcriptional responses, the method achieves more precise and effective control of HIV replication and T-cell survival compared to direct immune modulation approaches.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively increases or reduces immune responses as needed, enhancing CD4+ T-cell activity or Treg cell numbers, potentially aiding in managing HIV infection and autoimmune disorders by modulating NF-κB and FoxP3 deacetylation.
Implementation Method 1
SIRT1 binds and deacetylates Tat at K50, a process necessary to recycle nonacetylated Tat protein for binding to TAR RNA and the cellular positive transcription elongation factor b (P-TEFb)
Data Source
AI summary
The present disclosure provides a method of increasing an immune response in an individual, the method involving administering to an individual in need thereof an inhibitor of SIRT1. The present disclosure provides a method of reducing an immune response, e.g., to treat chronic immune hyperactivity, the method generally involving administering to an individual in need thereof an activator of SIRT1. The present disclosure provides a method of modulating activation and differentiation of CD4+ T cells.